logo

Mersana Therapeutics, Inc. (MRSN)



Trade MRSN now with
  Date
  Headline
8/20/2019 8:07:59 AM Mersana Therapeutics Begins Expansion Study Of XMT-1536 In Patients With Platinum-Resistant Ovarian Cancer And NSCLC
3/8/2019 6:08:36 AM Mersana Therapeutics Q4 Net Loss $22.4 Mln Or $0.97/Shr Vs Loss Of $14.0 Mln Or $0.61/Shr Last Year
3/1/2019 7:09:50 AM Mersana Therapeutics Announces Pricing Of Public Offering Of 21.25 Mln Shares At $4/Shr
1/7/2019 7:34:49 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) FY19 Estimate To -2.79 From -2.48
1/7/2019 7:34:27 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) Q4 19 Estimate To -0.70 From -0.63
1/7/2019 7:34:21 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q3 19 Estimate To -0.70 From -0.63
1/7/2019 7:34:06 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q2 19 Estimate To -0.69 From -0.61
1/7/2019 7:33:58 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q1 19 Estimate To -0.69 From -0.61
1/7/2019 7:29:32 AM Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $15 Price Target
1/4/2019 7:05:03 AM Mersana Therapeutics Announces Strategic Priorities And Goals For 2019 And Beyond
11/13/2018 7:11:33 AM Mersana Therapeutics Q3 Loss Per Share $0.75 Vs Loss $0.35 Last Year
11/12/2018 9:16:29 AM Mersana Presents Pre-clinical Data At AACR-NCI-EORTC On Two Additional, Proprietary Antibody Drug Conjugate Platform
9/25/2018 8:06:19 AM Mersana Therapeutics Presents New Preclinical Data On XMT-1536 At IASLC
9/18/2018 6:40:24 AM Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $15 Down From $16 Price Target
9/17/2018 7:03:50 AM Mersana Therapeutics: FDA Lifts Partial Clinical Hold For XMT-1522
8/14/2018 4:27:13 PM Mersana Therapeutics Q2 Loss/share $0.54 Vs. Loss $6.33 Year Ago
  
 
>